BioSpace News Archive

Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, has announced that it will be presenting at the H.C. Wainwright BioConnect 2021 Conference, being held virtually between January 11-14, 2021.

Mirum Pharmaceuticals, Inc. announced that on January 8, 2021, the Compensation Committee of Mirum’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 49,900 shares of common stock to five new employees under Mirum’s 2020 Inducement Plan.

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced an equity investment of $12.5 million in VISEN Pharmaceuticals (VISEN) as part of VISEN’s $150 million Series B financing.

Please note that the embedded hyperlinks in the press release below have been corrected from a release issued under the same headline earlier today. Cullinan Management, Inc. , a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients, announced today the pricing of its upsized initial public offering of 11,900,000 shares of c

In order to up their sales and revenues, savvy companies in the global guidewires market are expending time and money on research and development of better products having sophisticated features to cater to various medical procedures.

The global ophthalmic surgical technologies market is a growing market thanks to the rising investment flooding into the healthcare sector at present.

Icosabutate demonstrates potent anti-inflammatory, anti-fibrotic and antioxidant properties, and shows improvement in cardio-metabolic risk profile

Aurinia Pharmaceuticals Inc. announced that members of the management team will participate in two upcoming virtual investor conferences and participate in a panel discussion hosted by Dr. Scott Gottlieb, former FDA Commissioner

Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its fourth-quarter and full-year 2020 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EST on Thursday, Feb. 4. During the call, company executives will provide an overview of Merck’s performance for the quarter. Investors, journalists and the general public may access a live audio webcast of the

- Celularity has entered into a definitive merger agreement with GX Acquisition Corp. upon closing, shares of the combined company will be listed on Nasdaq under the ticker symbol “CELU”. - Institutional investors and certain individuals have committed to invest approximately $80 million through concurrent equity investments - $372 million of total expected proceeds from the PIPE and cash held in GX Acquisition